Development of Autologous Serum Eyes Drops Preparing Processes for Patients with Ocular Surface Disease
Article Sidebar
Main Article Content
Abstract
The formal processes for producing autologous blood serum eye drops (ASED) include a 2-hour incubation time and a 15-minute centrifugal time. Therefore, the main objectives of this Quasi-experimental study (manipulation and control only, without randomization) are (1) to reduce the processing time of the standard procedures of preparing the autologous serum eye drops, and (2) to compare the biochemical properties (pH and osmolality) of ASED from the developed processes with those of the standard one. After establishing the developed processes with a 0.5-hour incubation time and a 5-minute centrifugal time and observing the experimental data, the ANOVA statistic method, Kruskal-Wallis Test, and Bland-Altman Plot, were used to analyze the data.
The experimental results show that the pH and osmolality values of ASED from the developed processes and those of the standard procedure are similar, and the insignificant differences are acceptable. The pH and osmolality are 7.5-7.7 and 289-296 mmol/L, respectively, which are in the standard range. Therefore, it can be concluded that the developed processes can be implemented, resulting in a reduction of waiting time from 4 hours to 1.5 hours and allowing patients to receive autologous serum eye drops faster than the previous procedures.
Article Details
References
Lemp MA., 2004, Management of dry eye disease, Am J Manage Care;14 Suppl 3:S88-101
Foulks GN., 2008, Pharmacological management of dry eye in the elderly patient, Drugs Aging; 25:105-18
Dogru M., Tsubota K., 2011, Pharmacotherapy of dry eye, Expert Opin Pharmacother, 12:325-34
Gicquel JJ., Bremond-Gignac D., 2013, Emerging treatments for dry eye: Some like it hot while others may prefer a good stimulation, Br J Ophthalmol., 97:53-40
Sandra L., Valencia Castillo, Esther Saez Martin, Luis J. Garcia Frade and F. Javier G., 2021, Autologous serum eye drops improve tear production, both lachrymal flow and stability tests and conjunctival impression cytology with transfer in dry eye disease, Blood Transfus, 19:45-53
Wimolwan T. J., 2558, Dry Eyes Disease Text Book, Mor Chow Ban Publisher, ISBN978-616-374-9369 (in Thai)
Pinnita Tanthuvanit, 2020, Dry Eye Syndrome (Management Recommendations), American Academy of Ophthalmology
Celebi AR,Ulusoy C, & Mirza GE., 2014, The efficacy of autologous serum eye drops for severe dry syndrome: a randomized double-blind crossover study, Graefes Arch clin Exp OpHthalmol., 252(4):619-626.
Liu Y, Hirayama M, & Cui X., 2015, Effectiveness of autologous serum eye drops combined with punctual plugs for the treatment of Sjogren syndromerelated dry eye, Cornea., 34(10):1214-1220.
Lee GA, & Chen SX., 2008, Autologous serum in the management of recalcitrant dry eye syndrome, Clin Exp OpHthalmol., 36(2):119-122.
Shi-yin Pan et al., 2011, Tear Osmolality molarity and dry eye, Chinese Journal of Ophthalmology, 47(05): 475-477.
Papa V. et al., 2001, Comparison of hypotonic and isotonic solutions containing sodium hyaluronate on the symptomatic treatment of dry eye patients, OpHthalmologica, 215(2):124-7
Aragona P., G Di Stefano, F Ferreri, R Spinella and A Stilo, 2002, Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren’s syndrome patient, Br J Ophthalmol, 86(8), 879-884
Sandro L.V.C., Esther S.M., Luis J.G.F., and Javier G.M., 2021, Autologous serum eye drops improve tear production, both lachrymal flow and stability tests and conjunctival impression cytology with transfer in dry eye disease, Blood Transfus., 19:45-53
Jay C.B., Jan S., Rachael H.B., and Sandra M.B., 2009, Time- and Temperature-Dependent Stability of Growth Factor Peptides in Human Autologous Serum Eye Drops, Cornea., vol 28
Noble B, Loh R, MacLenna S, Pesudovs K, and Quereshi S., 2004, Comparison of autologous serum eye drops with conventional therapy in a randomized crossover trial for ocular surface disease, Br J Ophthalmol., 88:647-652
Poon AC, Geerling G, Dart JK, Fraenkel GE, & Daniels JT., 2001, Autologous serum eyedrops of dry eyes and epithelial defects: clinical and invitro toxicity studies, Br J Ophthalmol., 85:118-1197
Geerling Gerd, and Dirk Hartwig., 2004, Autologous Surum Eyedrops for Ocular Surface Disorders, Cornea and External Eye Disease, Vol1
Hye R.L., Yun J.H., Soie C, Sang M.H., and Kyou S.H., 2014, Proposal of standardized guidelines for the production and quality
control of autologous serum eye drops in Korea: based on a nationwide survey, Trasfusion, 54:1864-1870
Dugrillon A, Lauber S, Nguyen X, and Klueter H., 2002, Platelets applied to wounds and in tissue regeneration: induction of proliferation apoptosis by platelet membranes, Kluwer Academic/Plenum, Amsterdam, 70-71
Tsubota K, Goto E, Shimmura S, and Shimazaki J., 1999, Treatment of persistent corneal epithelial defect by autologous serum application, Ophthalmology., 106:1984-1989
Guilherme GQ, Mauro C, and Ashley B., 2008, Autologous serum for ocular surface diseases, Arq Bras Oftalmol., 71:47-54
Victor J.D., Ching L.T., Jarard S., and Thierry B., 2018, Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood
Products, Frontiers in Medicine, 18
Bennie H. Jeng and William J.Cupps., 2009, Autologous Serum 50% Eyedrops in the Treatment of Persistent Corneal Epithelial Defects, Cornea, Vol 28:1104-1108
Sabahattin Sul, Safak K, Goksu A., Pelin O., and Erhan O., 2018, Application of autologous serum eye drops after pterygium surgery: a prospective study, Graefe’s Archive for Clinical and Experimental Ophthalmology, 256:1939-1943
Joanna V.H., Maria E. and Madeleine Z., 2016, The use of autologous serum for the treatment of ocular surface disease at Swedish tertiary referral center, Int. Medical Case Reports Journal, Vol 9, 47-54
Munira H., Roni M.S., Alan A., 2014, Longterm Use of Autologous Serum 50% Eye Drops for the Treatment of Dry Eye Disease, Cornea, Vol 33
Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, & McCarty DJ., 2001, Controlled study of the use of autologous serum in dry eye patients, Cornea, 20(8): 802-6.
Sriwidodo S, Insan S.K.S., Iman P.M., Toto S. Ulvi Z, and Kakhar U., 2020, Stabilization of eye drops containing autologous serum
and recombinant human epidermal growth factor for dry eye syndrome, Journal of Advance Pharmaceutical Tech., 11(4): 184-188
Matsumoto Y., Dogru M., 2004, Autologous Serum Application in the Treatment of Neurotrophic Keratopathy, The American Academy of Ophthalmology
Goto E., Shimmura S. and Tsubota K., 2001, Treatment of Superior Limbic keratoconjunctivitis by Application of Autologous Serum, Cornea, Vol 20, 807-810
Del C., 2002, Treatment of Recurrent Corneal Erosions Using Autologous Serum, Cornea, Vol 21, 781-3
Mirjana A., Marko P., Dragan V. and Katarian J., 2013, Autologous Serum Eye Drops for Post-Chemical Injuries and Corneal Epithelial Defects, OA Maced J Med Sci., 1(1), 45-49
Amir A. and Christopher J., 2015, Autologous Serum Eye Drops for the Treatment of Ocular Surface Disease, Eye & Contact Lens, Vol 41
I-Hsin M., Lily W.C., Wen-Hui T., and Wei-Li C., 2017, Serum components and clinical efficacies of autologous serum eye drops in dry eye patients with active and inactive Sjogren syndrome, Taiwan J Ophthalmol, 7:213-220
Lui L., Hartwig D., Harloff S., Herminghaus P., Geerling G., 2005, An optimized protocol for the production of autologous serum
eyedrops, Graefes Arch Clin Exp Ophthalmol., Jul;243(7); 706-14
Westland JC., 2010, Lower bounds on sample size in structural equation modeling, Electronic Commerce Research and Applications, 476-487
Anitua E., Muruzabal F., and Riestra A., 2015, Autologous serum and plasma rich in growth factors in ophthalmology: Preclinical and clinical studies, Acta Ophthalmal, 93:605-14